The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis
Open accessAbstract
Cyclooxygenase-2 (COX-2), the enzyme at the rate-limiting step of prostanoid production, has been found to be overexpressed in human lung cancer. To evaluate lung tumor COX-2 modulation of antitumor immunity, we studied the antitumor effect of specific genetic or pharmacological inhibition of COX-2 in a murine Lewis lung carcinoma (3LL) model. Inhibition of COX-2 led to marked lymphocytic infiltration of the tumor and reduced tumor growth. Treatment of mice with anti-PGE2 mAb replicated the growth reduction seen in tumor-bearing mice treated with COX-2 inhibitors. COX-2 inhibition was accompanied by a significant decrement in IL-10 and a concomitant restoration of IL-12 production by APCs. Because the COX-2 metabolite PGE2 is a potent inducer of IL-10, it was hypothesized that COX-2 inhibition led to antitumor responses by down-regulating production of this potent immunosuppressive cytokine. In support of this concept, transfer of IL-10 transgenic T lymphocytes that overexpress IL-10 under control of the IL-2 promoter reversed the COX-2 inhibitor-induced antitumor response. We conclude that abrogation of COX-2 expression promotes antitumor reactivity by restoring the balance of IL-10 and IL-12 in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cyclooxygenase in biology and disease
DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., van de Putte, L. B. A., & Lipsky, P. E. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1063 · Cited by 2,506
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272
Tsujii, M., & DuBois, R. N. (1995) · Cell · doi:10.1016/0092-8674(95)90127-2 · Cited by 2,267
Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2
Smith, W. L., Garavito, R. M., & DeWitt, D. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33157 · Cited by 1,978
de Waal Malefyt, R., Haanen, J., Spits, H., Roncarolo, M. G., te Velde, A., Figdor, C., Johnson, K., Kastelein, R., Yssel, H., & de Vries, J. E. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.4.915 · Cited by 1,930
IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells
Fiorentino, D. F., Zlotnik, A., Vieira, P., Mosmann, T. R., Howard, M., Moore, K. W., & O’Garra, A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.10.3444 · Cited by 1,865
Hla, T., & Neilson, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7384 · Cited by 1,465
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
Tsujii, M., Kawano, S., & DuBois, R. N. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3336 · Cited by 1,398
Herschman, H. R. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(95)00194-8 · Cited by 1,197
Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., & Gately, M. K. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.4.1223 · Cited by 1,197
Expression of cyclooxygenase-1 and -2 in human colorectal cancer.
Sano, H., Kawahito, Y., Wilder, R. L., Hashiramoto, A., Mukai, S., Asai, K., Kimura, S., Kato, H., Kondo, M., & Hla, T. (1995) · PubMed · Cited by 1,126
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.
Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D., & Dubois, R. N. (1998) · PubMed · Cited by 1,114
Interleukin-12 and its role in the generation of TH1 cells
Trinchieri, G. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90230-i · Cited by 845
Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.
Kargman, S., O’Neill, G. P., Vickers, P. J., Evans, J. F., Mancini, J. A., & Jothy, S. (1995) · PubMed · Cited by 824
cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.
O'Banion, M. K., Winn, V. D., & Young, D. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.4888 · Cited by 821
Expression of cyclooxygenase-2 in human gastric carcinoma.
Ristimäki, A., Honkanen, N., Jänkälä, H., Sipponen, P., & Härkönen, M. (1997) · PubMed · Cited by 813
Anti-inflammatory drugs and their mechanism of action
Vane, J. R., & Botting, R. M. (1998) · Inflammation Research · doi:10.1007/s000110050284 · Cited by 798
Recombinant IL-12 administration induces tumor regression in association with IFN- gamma production.
Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.4.1697 · Cited by 780
The role of IL-10 in crossregulation of TH1 and TH2 responses
Mosmann, T. R., & Moore, K. W. (1991) · Immunology Today · doi:10.1016/s0167-5699(05)80015-5 · Cited by 768
Inhibition of Angiogenesis In Vivo by Interleukin 12
Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., & Folkman, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.8.581 · Cited by 722
Expression of cyclooxygenase-2 in human lung carcinoma.
Wolff, H. J., Saukkonen, K., Anttila, S. L., Karjalainen, A., Vainio, H., & Ristimaki, A. P. (1998) · PubMed · Cited by 717
Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.
Chan, G. G., Boyle, J. O., Yang, E. K., Zhang, F., Sacks, P. G., Shah, J. P., Edelstein, D. R., Soslow, R. A., Koki, A. T., Woerner, B. M., et al. (1999) · PubMed · Cited by 706
Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.
Tucker, O., Dannenberg, A. J., Yang, E. K., Zhang, F., Teng, L., Daly, J. M., Soslow, R. A., Masferrer, J. L., Woerner, B. M., Koki, A. T., et al. (1999) · PubMed · Cited by 692
Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production.
van der Pouw Kraan, T. C., Boeije, L. C., Smeenk, R. J., Wijdenes, J., & Aarden, L. A. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.2.775 · Cited by 666
Hanif, R., Pittas, A., Feng, Y., Koutsos, M. I., Qiao, L., Staiano-Coico, L., Shiff, S. I., & Rigas, B. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00181-5 · Cited by 608
Wilson, K. T., Fu, S., Ramanujam, K. S., & Meltzer, S. J. (1998) · PubMed · Cited by 591
Huang, M., Stolina, M., Sharma, S. P., Mao, J. T., Zhu, L. X., Miller, P. W., Wollman, J. S., Herschman, H. R., & Dubinett, S. M. (1998) · PubMed · Cited by 492
Self-citationDexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene.
Kujubu, D. A., & Herschman, H. R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42398-8 · Cited by 402
Piazza, G. A., Rahm, A. K., Finn, T. S., Fryer, B., Li, H., Stoumen, A. L., Pamukcu, R., & Ahnen, D. J. (1997) · PubMed · Cited by 375
Strassmann, G., Patil-Koota, V, Finkelman, F., Fong, M., & Kambayashi, T. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.6.2365 · Cited by 367
The host—tumor immune conflict: from immunosuppression to resistance and destruction
Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F., Caignard, A., & Blay, J. Y. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01115-8 · Cited by 350
Tahara, H., Zeh, H. J., Storkus, W. J., Pappo, I., Watkins, S. C., Gubler, U., Wolf, S. F., Robbins, P., & Lotze, M. T. (1994) · PubMed · Cited by 326
Kim, J., Modlin, R. L., Moy, R. L., Dubinett, S. M., McHugh, T., Nickoloff, B. J., & Uyemura, K. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.4.2240 · Cited by 323
Self-citationMatsuda, M., Salazar, F., Petersson, M., Masucci, G., Hansson, J., Pisa, P., Zhang, Q. J., Masucci, M. G., & Kiessling, R. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.6.2371 · Cited by 306
Smith, W. L., & DeWitt, D. L. (1995) · PubMed · Cited by 283
Murata, H. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(98)00757-6 · Cited by 279
Maeda, H., & Shiraishi, A. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.1.73 · Cited by 272
Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., & Lotze, M. T. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.12.6466 · Cited by 271
Altered Immune Responses in Interleukin 10 Transgenic Mice
Hagenbaugh, A., Sharma, S., Dubinett, S. M., Wei, S. H.-Y., Aranda, R., Cheroutre, H., Fowell, D. J., Binder, S., Tsao, B., Locksley, R. M., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.12.2101 · Cited by 269
Self-citationHuman non-small cell lung cancer cells express a type 2 cytokine pattern
(1996) · Lung Cancer · doi:10.1016/0169-5002(96)85851-x · Cited by 257
Liu, X., & Rose, D. P. (1996) · PubMed · Cited by 243
Alleva, D. G., Burger, C. J., & Elgert, K. D. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.4.1674 · Cited by 241
Qin, Z., Noffz, G., Mohaupt, M., & Blankenstein, T. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.2.770 · Cited by 193
IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells.
Beissert, S., Hosoi, J., Grabbe, S., Asahina, A., & Granstein, R. D. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.3.1280 · Cited by 184
Huang, M., Sharma, S. P., Mao, J. T., & Dubinett, S. (1996) · Journal of Immunology · doi:10.4049/jimmunol.157.12.5512 · Cited by 184
Self-citationCyclooxygenase-2 expression in hepatocellular carcinoma.
Shiota, G., Okubo, M., Noumi, T., Noguchi, N., Oyama, K., Takano, Y., Yashima, K., Kishimoto, Y., & Kawasaki, H. (1999) · PubMed · Cited by 174
Amount of interleukin 12 available at the tumor site is critical for tumor regression.
Colombo, M. P., Vagliani, M., Spreafico, F., Parenza, M., Chiodoni, C., Melani, C. C., & Stoppacciaro, A. (1996) · PubMed · Cited by 174
Kobayashi, M., Kobayashi, H., Pollard, R. B., & Suzuki, F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.12.5869 · Cited by 171
Halak, B. K., Maguire, H., & Lattime, E. C. (1999) · PubMed · Cited by 158
Mitra, R. S., Judge, T. A., Nestle, F. O., Turka, L. A., & Nickoloff, B. J. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.6.2668 · Cited by 156
Cavallo, F., Carlo, E. D., Butera, M., Verrua, R., Colombo, M. P., Musiani, P., & Forni, G. (1999) · PubMed · Cited by 137
B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
Coughlin, C. M., Wysocka, M., Kurzawa, H., Lee, W. M. F., Trinchieri, G., & Eck, S. L. (1995) · PubMed · Cited by 115
Gambotto, A. A., Tüting, T., McVey, D., Kovesdi, I., Tahara, H., Lotze, M. T., & Robbins, P. D. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700013 · Cited by 78
Asano, K., Lilly, C. M., & Drazen, J. M. (1996) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1996.271.1.l126 · Cited by 76
Kawata, R., Reddy, S. T., Wolner, B. S., & Herschman, H. R. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.2.818 · Cited by 71
Sharma, S. P., Miller, P. W., Stolina, M., Zhu, L., Huang, M., Paul, R. W., & Dubinett, S. M. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300531 · Cited by 66
Self-citationBianchi, R., Grohmann, U., Belladonna, M. L., Silla, S., Fallarino, F., Ayroldi, E., Fioretti, M. C., & Puccetti, P. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.4.1589 · Cited by 59
Walenga, R. W., KESTER, M. A., Coroneos, E., Butcher, S., Dwivedi, R., & Statt, C. (1996) · Prostaglandins · doi:10.1016/s0090-6980(96)00101-3 · Cited by 51
Dubinett, S. M., Miller, P. W., Sharma, S. P., & Batra, R. K. (1998) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70009-5 · Cited by 48
Self-citationThe tis Genes, Primary Response Genes Induced by Growth Factors and Tumor Promoters in 3T3 Cells
Herschman, H. R., Kujubu, D. A., Fletcher, B. S., Ma, Q., Varnum, B. C., Gilbert, R. S., & Reddy, S. T. (1994) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)60251-2 · Cited by 29
Nabioullin, R., Sone, S., Nil, A., Haku, T., & Ogura, T. (1994) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1994.tb02958.x · Cited by 17
Cited by
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Self-citationWang, D., & DuBois, R. N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2809 · Cited by 1,793
Regulation of Immune Responses by Prostaglandin E2
Kalinski, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101029 · Cited by 1,474
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
Greenhough, A., Smartt, H. J. M., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., & Kaidi, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp014 · Cited by 1,220
“Furthermore, in vivo studies have revealed that prevention of adenoma development in FAP patients is more effective when tissue prostaglandin levels are reduced through NSAID treatment [38], and more specifically, sequestration of PGE2 by administration of a PGE2 monoclonal antibody in mice has been demonstrated suffi…”
Background
Metadata
- Authors
- Stolina, M., Sharma, S., Lin, Y., Dohadwala, M., Gardner, B., Luo, J., Zhu, L., Kronenberg, M., Miller, P. W., Portanova, J., Lee, J. C., & Dubinett, S. M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-01-01
- Volume
- 164
- Issue
- 1
- Pages
- 361-370
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2146708145
- Cited by
- 465
- References
- 61
- FWCI
- 18.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.